Castle Biosciences (CSTL) to Release Earnings on Wednesday

Key Points

• Q1 2026 earnings release: Castle Biosciences will report results after the close on Wednesday, May 6, with analysts projecting EPS of ($0.4888) and revenue of $79.284 million (conference call at 4:30 PM ET).
• Analyst outlook: The stock carries a consensus rating of "Moderate Buy" with an average price target of $46.14, backed by multiple recent buy/outperform revisions.
• Insider activity and stock snapshot: Insiders sold 78,592 shares (~$2.11M) in the last 90 days while institutions own 92.6% of the stock; CSTL recently traded near $24.67 with a market cap around $747M.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) is expected to release its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Castle Biosciences to post earnings of ($0.4888) per share and revenue of $79.2840 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.15. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%.The business had revenue of $81.88 million for the quarter, compared to the consensus estimate of $81.19 million. On average, analysts expect Castle Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Castle Biosciences Stock Down 1.2%

Shares of CSTL stock opened at $24.67 on Wednesday. The stock's 50 day simple moving average is $26.13 and its 200 day simple moving average is $32.11. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.11 and a current ratio of 5.26. Castle Biosciences has a twelve month low of $14.59 and a twelve month high of $44.28. The company has a market capitalization of $747.47 million, a price-to-earnings ratio of -29.02 and a beta of 1.18.

Analysts Set New Price Targets

CSTL has been the topic of a number of recent analyst reports. Lake Street Capital raised their price objective on Castle Biosciences from $35.00 to $52.00 and gave the company a "buy" rating in a research note on Monday, January 12th. Robert W. Baird raised their price objective on Castle Biosciences from $41.00 to $44.00 and gave the company an "outperform" rating in a research note on Friday, February 27th. Canaccord Genuity Group cut their price objective on Castle Biosciences from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, April 20th. Zacks Research downgraded Castle Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Monday, March 2nd. Finally, Morgan Stanley raised Castle Biosciences to a "buy" rating in a research note on Monday, March 2nd. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Castle Biosciences presently has an average rating of "Moderate Buy" and a consensus target price of $46.14.

Insiders Place Their Bets

In other Castle Biosciences news, Director G Bradley Cole sold 7,403 shares of Castle Biosciences stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $28.47, for a total value of $210,763.41. Following the transaction, the director directly owned 19,309 shares of the company's stock, valued at $549,727.23. The trade was a 27.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Derek J. Maetzold sold 18,650 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $25.93, for a total value of $483,594.50. Following the completion of the transaction, the insider directly owned 22,129 shares in the company, valued at approximately $573,804.97. This represents a 45.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 78,592 shares of company stock valued at $2,107,094. Corporate insiders own 6.10% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. HRT Financial LP increased its position in Castle Biosciences by 0.9% in the 4th quarter. HRT Financial LP now owns 47,654 shares of the company's stock worth $1,853,000 after buying an additional 415 shares during the period. Franklin Resources Inc. increased its position in Castle Biosciences by 0.5% in the 3rd quarter. Franklin Resources Inc. now owns 99,787 shares of the company's stock worth $2,272,000 after buying an additional 540 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Castle Biosciences by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company's stock worth $309,000 after purchasing an additional 655 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Castle Biosciences during the fourth quarter valued at approximately $26,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Castle Biosciences during the fourth quarter valued at approximately $35,000. 92.60% of the stock is owned by institutional investors.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.